ArticleJournal of immunology (Baltimore, Md. : 1950)2013
Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help.
Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 47 citations in OpenAlex.
- Engaging Broader Stakeholders to Accelerate Group AVaccines · 2025Review
- Evaluation of Peptide-Based Vaccines AgainstVaccines · 2025Article
- The burden of group AiScience · 2025Review
- Disruption of IL-17-mediated immunosurveillance in the respiratory mucosa results in invasiveFrontiers in immunology · 2024Article
- A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils.Nature communications · 2023Article
- Insertion of an immunodominant T helper cell epitope within the Group AFrontiers in immunology · 2023Article
- Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines.Scientific reports · 2021Article
- Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.Clinical & translational immunology · 2021Article
- M-protein based vaccine induces immunogenicity and protection fromNPJ vaccines · 2020Article
- Host Pathways of Hemostasis that Regulate Group A Streptococcus pyogenes Pathogenicity.Current drug targets · 2020Article
- Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus.Vaccines · 2019Review
- Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8.Vaccine · 2018Article
- Molecular Epidemiology, Ecology, and Evolution of Group A Streptococci.Microbiology spectrum · 2018Review
- Contribution of cryptic epitopes in designing a group A streptococcal vaccine.Human vaccines & immunotherapeutics · 2018Article
- Skin infection boosts memory B-cells specific for a cryptic vaccine epitope of group A streptococcus and broadens the immune response to enhance vaccine efficacy.NPJ vaccines · 2018Article
- Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.Scientific reports · 2017Article
- Streptococcal Immunity Is Constrained by Lack of Immunological Memory following a Single Episode of Pyoderma.PLoS pathogens · 2016Article
- Article
- Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG.The Journal of infection · 2016Article
- The quest for GAS vaccine.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Streptococcus pyogenes (group A Streptococcus [GAS]) is a leading human pathogen associated with a diverse array of mucosal and systemic infections. Vaccination with J8, a conserved region synthetic peptide derived from the M-protein of GAS and containing only 12 aa from GAS, when conjugated to diphtheria toxoid, has been shown to protect mice against a lethal GAS challenge. Protection has been previously shown to be Ab-mediated. J8 does not contain a dominant GAS-specific T cell epitope. The current study examined long-term Ab memory and dissected the role of B and T cells. Our results demonstrated that vaccination generates specific memory B cells (MBC) and long-lasting Ab responses. The MBC response can be activated following boost with Ag or limiting numbers of whole bacteria. We further show that these memory responses protect against systemic infection with GAS. T cell help is required for activation of MBC but can be provided by naive T cells responding directly to GAS at the time of infection. Thus, individuals whose T cells do not recognize the short synthetic peptide in the vaccine will be able to generate a protective and rapid memory Ab response at the time of infection. These studies significantly strengthen previous findings, which showed that protection by the J8-diphtheria toxoid vaccine is Ab-mediated and suggest that in vaccine design for other organisms the source of T cell help for Ab responses need not be limited to sequences from the organism itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.